Pharmacological management of appetite expression in obesity (Q37710372)

22 August 2017

1 reference

title

Pharmacological management of appetite expression in obesity (English)

1 reference

22 August 2017

0 references

1 reference

1 reference

3

John E Blundell

1 reference

22 August 2017

Emma J Boyland

2

0 references

author name string

Jason C G Halford

series ordinal

1

1 reference

PubMed ID

20234354

22 August 2017

Tim C Kirkham

series ordinal

4

1 reference

PubMed ID

20234354

22 August 2017

Joanne A Harrold

series ordinal

5

1 reference

22 August 2017

16 March 2010

1 reference

Nature Reviews Endocrinology

22 August 2017

1 reference

22 August 2017

6

1 reference

22 August 2017

255-269

1 reference

22 August 2017

5

1 reference

https://scigraph.springernature.com/pub.10.1038/nrendo.2010.19

22 August 2017

0 references

cites work

Predictors of weight maintenance

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Psychological effects of dieting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Regulation of nutrient supply: the brain and appetite control.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Beyond-brand effect of television food advertisements on food choice in children: the effects of weight status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

The association of body weight, dietary intake, and energy expenditure with dietary restraint and disinhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Interaction between GLP-1 and CCK-33 in inhibiting food intake and appetite in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Peptide YY: a potential therapy for obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Inhibition of food intake in obese subjects by peptide YY3-36

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Pancreatic amylin as a centrally acting satiating hormone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Meta-analysis: pharmacologic treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Identifying the energy gap: magnitude and determinants of 5-year weight gain in midage women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Biological and psychological correlates of intermittent dieting behavior in young women. A model for bulimia nervosa.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Clinical pharmacotherapy for obesity: current drugs and those in advanced development.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Lipase inhibition attenuates the acute inhibitory effects of oral fat on food intake in healthy subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Cholinergic modulation of the Ca2+ response to bradykinin in neuroblastoma cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Low-dose leptin reverses skeletal muscle, autonomic, and neuroendocrine adaptations to maintenance of reduced weight

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Fasting leptin and appetite responses induced by a 4-day 65%-energy-restricted diet

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Separate systems for serotonin and leptin in appetite control

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Eating for pleasure or just wanting to eat? Reconsidering sensory hedonic responses as a driver of obesity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Liking vs. wanting food: importance for human appetite control and weight regulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

The human obesity gene map: the 2005 update

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Resistance and susceptibility to weight gain: individual variability in response to a high-fat diet

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Obesity associated genetic variation in FTO is associated with diminished satiety

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

An obesity-associated FTO gene variant and increased energy intake in children

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

The FTO gene and measured food intake in children

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Variation in the FTO gene influences food intake but not energy expenditure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Laboratory eating behavior in obesity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Experimental studies on food-intake in obese and normal weight subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Eating behavior in Prader-Willi syndrome, normal weight, and obese control groups

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Microanalysis of eating behavior of three leptin deficient adults treated with leptin therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Eating fast leads to obesity: findings based on self-administered questionnaires among middle-aged Japanese men and women.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

The joint impact on being overweight of self reported behaviours of eating quickly and eating until full: cross sectional survey

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Eating rate is a heritable phenotype related to weight in children

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Food intake and meal patterns of weight-stable and weight-gaining persons.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Acquired preference especially for dietary fat and obesity: a study of weight-discordant monozygotic twin pairs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Dietary fat and obesity: a review of animal, clinical and epidemiological studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Combined effects of energy density and portion size on energy intake in women.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Gastric capacity in normal, obese, and bulimic women.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Gastric capacity, test meal intake, and appetitive hormones in binge eating disorder

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Attenuated GLP-1 secretion in obesity: cause or consequence?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Glucagon-like peptide-1 release and satiety after a nutrient challenge in normal-weight and obese subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Attenuated peptide YY release in obese subjects is associated with reduced satiety.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Overconsumption and obesity: peptides and susceptibility to weight gain

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Altered hypothalamic function in response to glucose ingestion in obese humans.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Differential brain responses to satiation in obese and lean men

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Appetite and adiposity in children: evidence for a behavioral susceptibility theory of obesity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Differential activation of the dorsal striatum by high-calorie visual food stimuli in obese individuals.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Widespread reward-system activation in obese women in response to pictures of high-calorie foods.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Sweet tooth reconsidered: taste responsiveness in human obesity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Sensory preferences for fats: relationships with diet and body composition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Is susceptibility to weight gain characterized by homeostatic or hedonic risk factors for overconsumption?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Serotonergic drugs : effects on appetite expression and use for the treatment of obesity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Reproducibility, power and validity of visual analogue scales in assessment of appetite sensations in single test meal studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

The use of visual analogue scales to assess motivation to eat in human subjects: a review of their reliability and validity with an evaluation of new hand-held computerized systems for temporal tracking of appetite ratings

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Appetite sensations as a marker of overall intake.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Appetite sensations and satiety quotient: predictors of energy intake and weight loss.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Effect of anorexic drugs on food intake and the micro-structure of eating in human subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Effects of naltrexone on food intake and changes in subjective appetite during eating: evidence for opioid involvement in the appetizer effect

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

The effects of sibutramine on the microstructure of eating behaviour and energy expenditure in obese women

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Description and evaluation of a Newton-based electronic appetite rating system for temporal tracking of appetite in human subjects.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Diary methods: capturing life as it is lived

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Are electronic diaries useful for symptoms research? A systematic review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Ecological momentary assessment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Evaluating the Power of Food Scale in obese subjects and a general sample of individuals: development and measurement properties

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Psychometric analysis of the Three-Factor Eating Questionnaire-R21: results from a large diverse sample of obese and non-obese participants

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Psychometric properties and factor structure of the Three-Factor Eating Questionnaire (TFEQ) in obese men and women. Results from the Swedish Obese Subjects (SOS) study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Characterization of obese individuals who claim to detect no relationship between their eating pattern and sensations of hunger or fullness.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Eating behaviors and indexes of body composition in men and women from the Québec family study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Socioeconomic gradient in body size and obesity among women: the role of dietary restraint, disinhibition and hunger in the Whitehall II study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Association of body mass with dietary restraint and disinhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Eating behavior correlates of adult weight gain and obesity in healthy women aged 55-65 y.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

The Eating Inventory and body adiposity from leanness to massive obesity: a study of 2509 adults.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Food selection and eating behaviour during weight maintenance intervention and 2-y follow-up in obese men

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Familial Resemblance in Eating Behaviors in Men and Women from the Quebec Family Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Neuromedin beta: a strong candidate gene linking eating behaviors and susceptibility to obesity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Eating patterns and obesity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Binge eating disorder in extreme obesity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Prevalence and correlates of binge eating disorder in a community sample

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Who succeeds in maintaining weight loss? A conceptual review of factors associated with weight loss maintenance and weight regain

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Disinhibition: its effects on appetite and weight regulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Sibutramine treatment in obesity: initial eating behaviour in relation to weight loss results and changes in mood

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Who will lose weight on sibutramine and orlistat? Psychological correlates for treatment success.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Cholecystokinin is a satiety hormone in humans at physiological post-prandial plasma concentrations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Gut hormone PYY(3-36) physiologically inhibits food intake

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Stimulation of cholecystokinin-A receptors with GI181771X does not cause weight loss in overweight or obese patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.

31 March 2020

2 references

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

31 March 2020

12 December 2020

Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses.

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Glucagon-like peptide-1: a potent regulator of food intake in humans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Effects of a preload on reduction of food intake by GLP-1 in healthy subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Prandial subcutaneous injections of glucagon-like peptide-1 cause weight loss in obese human subjects.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)--preclinical and clinical results

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Treatment of type 2 diabetes with glucagon-like peptide-1 receptor agonists.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Oxyntomodulin suppresses appetite and reduces food intake in humans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Multiple regulation of peptide YY secretion in the digestive tract.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

PYY3-36 as an anti-obesity drug target.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

PYY modulation of cortical and hypothalamic brain areas predicts feeding behaviour in humans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Supraphysiological doses of intravenous PYY 3-36 cause nausea, but no additional reduction in food intake

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Effect of peptide YY3-36 on food intake in humans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Effect of subcutaneous injections of PYY1-36 and PYY3-36 on appetite, ad libitum energy intake, and plasma free fatty acid concentration in obese males.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Effects of PYY1–36 and PYY3–36 on appetite, energy intake, energy expenditure, glucose and fat metabolism in obese and lean subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Low-dose pramlintide reduced food intake and meal duration in healthy, normal-weight subjects.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Amylin, food intake, and obesity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Pramlintide treatment reduces 24-h caloric intake and meal sizes and improves control of eating in obese subjects: a 6-wk translational research study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Addition of pramlintide to insulin therapy lowers HbA1c in conjunction with weight loss in patients with type 2 diabetes approaching glycaemic targets

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Effects of recombinant leptin therapy in a child with congenital leptin deficiency.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Serotonergic drugs and valvular heart disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Sibutramine reduces food intake in non-dieting women with obesity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Short-term effects of sibutramine (Reductil) on appetite and eating behaviour and the long-term therapeutic outcome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

A Randomized, Double-blind, Placebo-Controlled Study of Sibutramine in the Treatment of Binge-Eating Disorder

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

An open-label trial of sibutramine in obese patients with binge-eating disorder.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Use of sibutramine, an inhibitor of the reuptake of serotonin and noradrenaline, in the treatment of binge eating disorder: a placebo-controlled study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Sibutramine-associated psychotic episode

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Sibutramine and panic attacks

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Blood pressure changes associated with sibutramine and weight management - an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes trial (SCOUT).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Activation of central melanocortin pathways by fenfluramine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Serotonin Reciprocally Regulates Melanocortin Neurons to Modulate Food Intake

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

m-Chlorophenylpiperazine decreases food intake in a test meal

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Hypophagic, endocrine and subjective responses tom-chlorophenylpiperazine in healthy men and women

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

5-HT2C receptor activation decreases appetite and body weight in obese subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Central serotonergic effects of m-chlorophenylpiperazine (mCPP) among normal control adolescents

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Discovery and SAR of new benzazepines as potent and selective 5-HT(2C) receptor agonists for the treatment of obesity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Lorcaserin (APD356), a selective 5-HT(2C) agonist, reduces body weight in obese men and women

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Tesofensine – a novel potent weight loss medicine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Tesofensine and weight loss

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

The brain, appetite, and obesity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Neuropeptide y receptor selective ligands in the treatment of obesity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Promising strategies for obesity pharmacotherapy: melanocortin-4 (MC-4) receptor agonists and melanin concentrating hormone (MCH) receptor-1 antagonists

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Naloxone, an opiate blocker, reduces the consumption of sweet high-fat foods in obese and lean female binge eaters

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Selective effects of naltrexone on food pleasantness and intake.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Effects of nalmefene on feeding in humans. Dissociation of hunger and palatability.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Lower pleasantness of palatable foods in nalmefene-treated human volunteers.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Effect of naltrexone on food intake, hunger, and satiety in obese men.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Effect of a tricyclic antidepressant and opiate antagonist on binge-eating behavior in normoweight bulimic and obese, binge-eating subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Naltrexone for the treatment of obesity: review and update

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Endocannabinoids in the regulation of appetite and body weight

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Abstinence symptoms following oral THC administration to humans.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Multiple-dose pharmacokinetics, pharmacodynamics, and safety of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, in healthy male volunteers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Bupropion and naltrexone: a review of their use individually and in combination for the treatment of obesity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

The anorectic effect of a long-acting preparation of phentermine (duromine)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Topiramate treatment for SSRI-induced weight gain in anxiety disorders.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Predictors of Weight Loss in Adults with Topiramate‐Treated Epilepsy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Zonisamide for weight loss in obese adults: a randomized controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Pharmacological approaches in the treatment of binge eating disorder.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Role of antiepileptic drugs in the management of eating disorders

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.19

The problem with weighing: effects on mood, self-esteem and body image

31 March 2020

1 reference

12 December 2020

Ghrelin enhances appetite and increases food intake in humans

1 reference

12 December 2020

Techniques for the experimental measurement of human eating behaviour and food intake: a practical guide

1 reference

12 December 2020

Eating behaviour in obese and normal weight 11-year-old children

1 reference

12 December 2020

Tesofensine, a monoamine reuptake inhibitor for the treatment of obesity

1 reference

12 December 2020

Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2.

1 reference

12 December 2020

Interacting appetite-regulating pathways in the hypothalamic regulation of body weight

1 reference

12 December 2020

Role of lipase in the regulation of upper gastrointestinal function in humans

1 reference

12 December 2020

Leptin reverses weight loss-induced changes in regional neural activity responses to visual food stimuli

1 reference

12 December 2020

Eating in public places: a review of reports of the direct observation of eating behavior

1 reference

12 December 2020

Physiology and pathophysiology of glucagon-like peptide-1 (GLP-1): the role of GLP-1 in the pathogenesis of diabetes mellitus, obesity, and stress.

1 reference

12 December 2020

Food fails to suppress ghrelin levels in obese humans.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRENDO.2010.19

1 reference

22 August 2017

1 reference

PubMed ID

20234354